MedTrace Logo

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-04-11

No results posted yet for this study

Summary

To assess the efficacy of Left Ventricular Hypertrophy (LVH) reduction and 24-hour blood pressure control of Valsartan 80mg or Nebivolol/Valsartan 5/80mg once daily as replacement therapy for currently treated or untreated hypertensive patients with LVH not at BP goal.

Conditions

  • Hypertension Complicated
  • Hypertrophy, Left Ventricular
  • Blood Pressure

Interventions

DRUG

Valsartan 80 mg

Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy

Sponsors & Collaborators

  • Allergan Sales, LLC

    collaborator INDUSTRY

  • Trinity Hypertension & Metabolic Research Institute

    lead OTHER

Principal Investigators

  • Henry A Punzi, MD · UT Southwestern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-07
Primary Completion
2018-01-25
Completion
2018-01-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03180593 on ClinicalTrials.gov